Keyword Search Subscribe to receive breaking news alerts about uniQure. Subscribe Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Date Title Sep 29, 2026 uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression Sep 02, 2026 uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease Jul 29, 2026 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update Jul 22, 2026 uniQure to Announce Second Quarter 2026 Financial Results Jun 25, 2026 uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares Jun 23, 2026 uniQure Announces Pricing of Upsized $225 Million Public Offering Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »